文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

清髓性与减低强度预处理造血细胞移植治疗急性髓系白血病和骨髓增生异常综合征的对比研究

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
PubMed 文献 · J Clin Oncol · 2017-02-13

这项III期随机试验比较清髓性预处理(MAC)与减低强度预处理(RIC)在急性髓系白血病或骨髓增生异常综合征患者中的效果,计划入组356例,因RIC组复发率显著高于MAC组(48.3% vs 13.5%,P<.001)而提前终止于272例。18个月总生存率MAC组77.5% vs RIC组67.7%(P=.07),差异未达统计学显著;RIC组治疗相关死亡率较低(4.4% vs 15.8%,P=.002),但MAC组无复发生存率显著更优(67.8% vs 47.3%,P<.01)。作者认为数据支持MAC作为适合患者的标准化疗方案。

要点

  • RIC组复发率显著高于MAC组(48.3% vs 13.5%,P<.001),试验因此提前终止。
  • 18个月总生存率MAC组77.5% vs RIC组67.7%(P=.07),差异未达统计学显著。
  • MAC组无复发生存率显著优于RIC组(67.8% vs 47.3%,P<.01),但治疗相关死亡率更高(15.8% vs 4.4%,P=.002)。

核心结论

  • MAC组总生存率高于RIC组,但差异未达统计学显著。
  • RIC组治疗相关死亡率较低,但复发率较高,MAC组无复发生存率具有统计学显著优势。
  • 这些数据支持将MAC作为适合的急性髓系白血病或骨髓增生异常综合征患者的标准治疗。

研究设计与样本

  • III期随机试验,比较MAC与RIC预处理后行异基因造血细胞移植的疗效。
  • 纳入年龄18至65岁、移植前合并症指数≤4且骨髓原始细胞<5%的急性髓系白血病或骨髓增生异常综合征患者。
  • 随机分配至MAC组(n=135)或RIC组(n=137),随后接受HLA相合同胞或无关供者移植。
  • 主要终点为随机分组后18个月总生存率,采用意向性治疗分析;次要终点包括无复发生存率和治疗相关死亡率。
  • 计划入组356例,因RIC组复发率高于MAC组而提前终止于272例。

主要发现

  • RIC组复发率为48.3%(95%CI 39.6%至56.4%),MAC组为13.5%(95%CI 8.3%至19.8%),P<.001。
  • 18个月总生存率:RIC组67.7%(95%CI 59.1%至74.9%)vs MAC组77.5%(95%CI 69.4%至83.7%),差异9.8%(95%CI -0.8%至20.3%),P=.07。
  • 治疗相关死亡率:RIC组4.4%(95%CI 1.8%至8.9%)vs MAC组15.8%(95%CI 10.2%至22.5%),P=.002。
  • 无复发生存率:RIC组47.3%(95%CI 38.7%至55.4%)vs MAC组67.8%(95%CI 59.1%至75%),P<.01。

临床怎么用

  • 作者结论指出,这些数据支持将MAC作为适合的急性髓系白血病或骨髓增生异常综合征患者的标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The optimal regimen intensity before allogeneic hematopoietic cell transplantation (HCT) is unknown. We hypothesized that lower treatment-related mortality (TRM) with reduced-intensity conditioning (RIC) would result in improved overall survival (OS) compared with myeloablative conditioning (MAC). To test this hypothesis, we performed a phase III randomized trial comparing MAC with RIC in patients with acute myeloid leukemia or myelodysplastic syndromes. Patients and Methods Patients age 18 to 65 years with HCT comorbidity index ≤ 4 and < 5% marrow myeloblasts pre-HCT were randomly assigned to receive MAC (n = 135) or RIC (n = 137) followed by HCT from HLA-matched related or unrelated donors. The primary end point was OS 18 months post-random assignment based on an intent-to-treat analysis. Secondary end points included relapse-free survival (RFS) and TRM. Results Planned enrollment was 356 patients; accrual ceased at 272 because of high relapse incidence with RIC versus MAC (48.3%; 95% CI, 39.6% to 56.4% and 13.5%; 95% CI, 8.3% to 19.8%, respectively; P < .001). At 18 months, OS for patients in the RIC arm was 67.7% (95% CI, 59.1% to 74.9%) versus 77.5% (95% CI, 69.4% to 83.7%) for those in the MAC arm (difference, 9.8%; 95% CI, -0.8% to 20.3%; P = .07). TRM with RIC was 4.4% (95% CI, 1.8% to 8.9%) versus 15.8% (95% CI, 10.2% to 22.5%) with MAC ( P = .002). RFS with RIC was 47.3% (95% CI, 38.7% to 55.4%) versus 67.8% (95% CI, 59.1% to 75%) with MAC ( P < .01). Conclusion OS was higher with MAC, but this was not statistically significant. RIC resulted in lower TRM but higher relapse rates compared with MAC, with a statistically significant advantage in RFS with MAC. These data support the use of MAC as the standard of care for fit patients with acute myeloid leukemia or myelodysplastic syndromes.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Scott BL, Pasquini MC, Logan BR, et al. Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. J Clin Oncol. 2017. PMID: 28380315. doi:10.1200/JCO.2016.70.7091

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。